Alvotech Clears A Path For 2024 Ustekinumab In Major Global Markets
Trio Of Licensing Agreements, Including In The EEA, Bolster Firm Amid US Delay
Alvotech has ensured there won’t be any legal hurdles to overcome as it plots launches via commercialization partners for its AVT04 proposed biosimilar to Stelara in major global markets.
